Levodopa
Approved · FDA / EMAAlso known as (-)-dopa, 3-Hydroxy-L-tyrosine, Atamet, Carbidopa-Levodopa+22 more
(-)-dopa, 3-Hydroxy-L-tyrosine, Atamet, Carbidopa-Levodopa, Crexont, Dhivy, Dihydroxy-L-phenylalanine, Dopar, Duopa, Inbrija, L-3-hydroxytyrosine, L-DOPA, LDOPA, Larodopa, Parcopa, Rytary, Sinemet, Stalevo, Vyalev, Levo-dopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, 3,4-Dihydroxy-L-phenylalanine, Carbidopa/Entacapone/Levodopa, L-3,4-dihydroxyphenylalanine, L-beta-(3,4-Dihydroxyphenyl)alanine, Levodopum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: LEVODOPA (NDA209184)
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
Label change: CARBIDOPA AND LEVODOPA (ANDA216505)
Dopaminergic Dysfunction in Late-Life Depression
Label change: LEVODOPA (NDA209184)
The role of L-DOPA in neurological and neurodegenerative complications: a review.
Approval: CARBIDOPA AND LEVODOPA (ANDA216505)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a… Show full indicationShow less
Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Dopaminergic Dysfunction in Late-Life Depression
Levodopa for Diabetic Retinopathy
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Brain : a journal of neurology2
- The New England journal of medicine2
- CNS drugs1
- Molecular and cellular biochemistry1
- Movement disorders : official journal of the Movement Disorder Society1
- Nature communications1
- Abbigeri MB1
- Adena MA1
- Amara AW1
- Ardouin C1
- Batir A1
- Belloso-Iguerategui A1
- Benabid AL1
- Benazzouz A1
- Columbia University2
- Center for Advancing Neurotechnological Innovation to Application (CRANIA)1
- Center for Applied Medical Research (CIMA)1
- Clinical Neuroproteomics Unit1
- Columbia University Medical Center1
- Department of Clinical and Biological Neurosciences1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 4 of the same disease areas as Levodopa in the shared literature.
Studied across 2 of the same disease areas as Levodopa in the shared literature.
Studied across the same disease area as Levodopa in the shared literature.
Studied across the same disease area as Levodopa in the shared literature.
Studied across the same disease area as Levodopa in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.